Transaction details
On March 19, 2026, Keith J. Sullivan, who previously served as both an officer and director of Neuronetics, Inc. (NASDAQ:STIM), completed the sale of 46,289 shares of the company’s common stock for approximately $62,027. The reported sale prices ranged from $1.20 to $1.48 per share. The company’s share price currently stands at $1.46, representing an 18.78% gain over the last week, despite a year-to-date decline of roughly 69%.
Reason for the sale and remaining ownership
The filings describe the trade as non-discretionary and executed to satisfy Sullivan’s tax withholding obligation upon vesting of a portion of a performance restricted stock unit (PRSU) award. After the transaction, Sullivan is listed as directly owning 1,590,924 shares of Neuronetics.
Financial and analyst context
According to an InvestingPro analysis cited in company materials, Neuronetics remains unprofitable over the most recent twelve-month period, with an EPS of -$0.59. The same analysis indicates that the platform’s Fair Value assessment suggests the shares are modestly undervalued at current levels. That analysis is part of broader Pro Research coverage available for STIM among other U.S. equities.
Recent operating results
In its fourth-quarter 2025 results, Neuronetics reported revenue of $41.8 million, exceeding the forecast of $40.66 million by a 2.73% positive surprise. Earnings per share, however, were reported at -$0.10, missing the expected -$0.09 and constituting an 11.11% negative surprise versus estimates.
Analyst reaction and leadership update
Canaccord adjusted its price target for Neuronetics downward from $7.00 to $3.00 while maintaining a Buy rating on the stock, reflecting an adjustment in valuation. Separately, the company announced Dan Reuvers as its new chief executive officer and noted that it achieved operationally positive cash flow in the second quarter.
These items together - an insider sale tied to RSU vesting, mixed quarterly results, a lower analyst price target, and an executive change - outline current developments at Neuronetics as investors and analysts continue to assess the company’s performance, valuation, and leadership direction.